NEW YORK (GenomeWeb News) – Protein Sciences has licensed its FluBiok recombinant influenza vaccine to Japanese biotech UMN Pharma to make and sell the product in that market.
 
Terms of the deal call for PSC to transfer technology to UMN, which will register, manufacture, market, and sell the vaccine in Japan for annual and pandemic use.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.